Isomorphic Labs stock
Private-market facts for current and former Isomorphic Labs employees researching their stock.
Overview
Alphabet subsidiary using AI and computational biology to reimagine the drug discovery process and develop new medicines.
Selling Isomorphic Labs shares
Why shareholders consider selling
Shareholders in Isomorphic Labs may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Isomorphic Labs does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Isomorphic Labs stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Isomorphic Labs shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Isomorphic Labs shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series A round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Isomorphic Labs shareholders
Exploring equity in Isomorphic Labs often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Isomorphic Labs most recently raised a Series A round .
Lead investors in this round include Alphabet.
Founders & company background
Isomorphic Labs was founded in 2021 by Demis Hassabis and is headquartered in London, United Kingdom.
Investors
Industry
Similar private companies
Latest Isomorphic Labs news
Frequently asked questions
- Is Isomorphic Labs still a private company?
- Yes, Isomorphic Labs is currently a private company.
- What is Isomorphic Labs's latest funding round?
- Isomorphic Labs's most recent known round is Series A.
- What is Isomorphic Labs's valuation?
- Isomorphic Labs's valuation has not been publicly disclosed.
- Who are the investors in Isomorphic Labs?
- Notable investors include Alphabet.
- Can I sell my Isomorphic Labs stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Isomorphic Labs stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Isomorphic Labs data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.